Nevertheless, emerging evidence indicates that the average distribution concentration of lapatinib in brain metastases was only 10–20% of the concentration found in peripheral metastases (15, 16), which can hardly treat the brain metastasis of HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.